Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease

Method comparison study of the Elecsys® β-Amyloid (1–42) CSF assay versus comparator assays and LC-MS/MS

(2019) Leslie M. Shaw et al.   CLINICAL BIOCHEMISTRY

Impact of Pre-Analytical Differences on Biomarkers in the ADNI and PPMI Studies: Implications in the Era of Classifying Disease Based on Biomarkers

(2019) Tessandra Stewart et al.   JOURNAL OF ALZHEIMERS DISEASE

Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of Alzheimer's disease

(2018) Min Shi et al.   Alzheimers & Dementia

CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts

(2018) Oskar Hansson et al.   Alzheimers & Dementia

CSF tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders

(2018) David J. Irwin et al.   NEUROLOGY

Evolution of cerebrospinal fluid total α-synuclein in Parkinson's disease

(2018) Marthe Gurine Førland et al.   PARKINSONISM & RELATED DISORDERS

Parkinson’s disease: evolution of cognitive impairment and CSF Aβ1–42 profiles in a prospective longitudinal study

(2018) Stefanie Lerche et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders

(2018) David G. Coughlin et al.   ANNALS OF NEUROLOGY

The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort

(2018) Kenneth Marek et al.   Annals of Clinical and Translational Neurology

Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study

(2017) Anette Schrag et al.   LANCET NEUROLOGY

Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis

(2017) David J Irwin et al.   LANCET NEUROLOGY

Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls

(2017) Brit Mollenhauer et al.   NEUROLOGY

Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease

(2017) Chelsea Caspell-Garcia et al.   PLoS One

CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study

(2016) Ju-Hee Kang et al.   ACTA NEUROPATHOLOGICA

Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1–42) in human cerebrospinal fluid

(2016) Tobias Bittner et al.   Alzheimers & Dementia

Cross-Sectional and Longitudinal Cognitive Correlates of FDDNP PET and CSF Amyloid-β and Tau in Parkinson’s Disease1

(2016) Mariateresa Buongiorno et al.   JOURNAL OF ALZHEIMERS DISEASE

Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease

(2016) Sara Hall et al.   MOVEMENT DISORDERS

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers

(2016) Clifford R. Jack et al.   NEUROLOGY

Phenotypic differences based on staging of Alzheimer's neuropathology in autopsy-confirmed dementia with Lewy bodies

(2016) Guerry M. Peavy et al.   PARKINSONISM & RELATED DISORDERS

CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease

(2015) Mark Terrelonge et al.   JOURNAL OF MOLECULAR NEUROSCIENCE

Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease

(2015) Daniel Weintraub et al.   MOVEMENT DISORDERS

Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study

(2015) Kathrin Brockmann et al.   PARKINSONISM & RELATED DISORDERS

CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease

(2015) Changqin Liu et al.   PARKINSONISM & RELATED DISORDERS

Alzheimer’s disease cerebrospinal fluid biomarkers are not influenced by gravity drip or aspiration extraction methodology

(2015) Alan Rembach et al.   Alzheimers Research & Therapy

Cerebrospinal Fluid α-Synuclein Predicts Cognitive Decline in Parkinson Disease Progression in the DATATOP Cohort

(2014) Tessandra Stewart et al.   AMERICAN JOURNAL OF PATHOLOGY

CSF A 42 predicts early-onset dementia in Parkinson disease

(2014) G. Alves et al.   NEUROLOGY

CSF biomarkers and clinical progression of Parkinson disease

(2014) S. Hall et al.   NEUROLOGY

Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease

(2013) Jing Zhang et al.   ACTA NEUROPATHOLOGICA

Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI

(2013) Jon B. Toledo et al.   ACTA NEUROPATHOLOGICA

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

(2013) Clifford R Jack et al.   LANCET NEUROLOGY

Neuropathologic substrates of Parkinson disease dementia

(2012) David J. Irwin et al.   ANNALS OF NEUROLOGY

Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders

(2012) Sara Hall et al.   ARCHIVES OF NEUROLOGY

An evaluation of the impact ofMAPT,SNCAandAPOEon the burden of Alzheimer's and Lewy body pathology

(2012) Christian Wider et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Cerebrospinal fluid amyloid-  and phenotypic heterogeneity in de novo Parkinson's disease

(2012) G. Alves et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines

(2012) Irene Litvan et al.   MOVEMENT DISORDERS

APOE ϵ4 Increases Risk for Dementia in Pure Synucleinopathies

(2012) Debby Tsuang et al.   JAMA Neurology

Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI

(2011) Leslie M. Shaw et al.   ACTA NEUROPATHOLOGICA

The Parkinson Progression Marker Initiative (PPMI)

(2011) Kenneth Marek et al.   PROGRESS IN NEUROBIOLOGY

CSF amyloid-  and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study

(2010) G. Alves et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

CSF Aβ42and tau in Parkinson's disease with cognitive impairment

(2010) Thomas J. Montine et al.   MOVEMENT DISORDERS

CSF amyloid   1-42 predicts cognitive decline in Parkinson disease

(2010) A. Siderowf et al.   NEUROLOGY

A clinico-pathological study of subtypes in Parkinson's disease

(2009) M. Selikhova et al.   BRAIN

Cerebrospinal fluid tau and ptau181increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease

(2009) Anne M. Fagan et al.   EMBO Molecular Medicine

Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease

(2009) Yaroslau Compta et al.   MOVEMENT DISORDERS